Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Pain Symptom Manage ; 67(1): 69-76, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-37769821

RESUMO

CONTEXT AND OBJECTIVES: To explore the feasibility of implementing the joint guideline on integrative medicine for pain management in oncology, published by the Society for Integrative Oncology (SIO) and the American Society of Clinical Oncology (ASCO), for integrative oncology (IO) services in supportive and palliative care. METHODS: A qualitative research methodology was co-designed by the SIO-ASCO guideline committee, with the Society for Complementary Medicine, Israel Medical Association (IMA). A questionnaire with five open-ended questions exploring barriers and enablers to implementing the guideline was distributed to chairs and board members of nine IMA-affiliated medical societies; four deans of Israeli medical schools; and nurses from the Israeli Society for Oncology Nursing. Respondent narratives were qualitatively analyzed using ATLAS.Ti software for systematic coding. RESULTS: Questionnaires were completed by 52 physicians and nurses from medical oncology, hematology, gynecological oncology, pediatric oncology, palliative medicine, pain, family medicine, internal medicine, and integrative medicine. The SIO-ASCO guidelines were endorsed by nine IMA-affiliated societies. The domains identified included the importance of guideline implementation in clinical practice; barriers and facilitators to implementation; practical aspects required for this implementation (e.g., IO training); clinical indications for referral; budget-related issues; and clinical and administrative models enabling practical implementation of the guideline. CONCLUSION: We found across-the-board consensus among the nine IMA-affiliated societies supporting the current guideline. This, while identifying potential facilitators and barriers in order to address the implementation of the SIO-ASCO guideline recommendations.


Assuntos
Oncologia Integrativa , Neoplasias , Criança , Humanos , Oncologia Integrativa/métodos , Israel , Neoplasias/terapia , Oncologia , Dor
2.
Pediatr Hematol Oncol ; 36(5): 255-266, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31424297

RESUMO

Medical marijuana (MM) is widespread in many medical fields, including oncology, with limited use in pediatric oncology where research is scarce and often shows conflicting results. This research focuses on alleviating side effects of anticancer treatment as an integral part of supportive and palliative care of children with cancer. We report our experience with MM treatment in 50 children, adolescents, and young adults with different types of cancer during 2010-2017. The main indications for prescriptions were nausea and vomiting, decreased mood, disturbed sleep, and pain. The medication was supplied to 30 patients via oil drops (60%) and 11 via smoking (22%), followed by vaporization, capsules, or combinations of various routes. Positive effects were reported by verbal children and parents in 80% of cases. MM was generally well tolerated with few patients reporting toxicity, with the most common adverse reactions being burning in the throat and anxiety attacks in subjects who chose to smoke the product. We conclude that MM may serve as a potentially useful complementary therapy to conventional supportive treatment of children suffering from cancer at the end of life. Further research is needed on the safety and efficacy and the consequences of prolonged use in pediatric populations.


Assuntos
Maconha Medicinal/administração & dosagem , Náusea/tratamento farmacológico , Neoplasias/tratamento farmacológico , Dor/tratamento farmacológico , Transtornos do Sono-Vigília/tratamento farmacológico , Vômito/tratamento farmacológico , Adolescente , Adulto , Criança , Pré-Escolar , Terapias Complementares , Feminino , Humanos , Masculino , Náusea/patologia , Náusea/fisiopatologia , Neoplasias/patologia , Neoplasias/fisiopatologia , Dor/patologia , Dor/fisiopatologia , Transtornos do Sono-Vigília/patologia , Transtornos do Sono-Vigília/fisiopatologia , Vômito/patologia , Vômito/fisiopatologia
3.
J Pediatr Hematol Oncol ; 41(4): e201-e205, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-30499908

RESUMO

BACKGROUND: It is currently expected that about 20% of children with cancer will ultimately die. Writing advanced life directives sufficiently long before the actual death of a child ensues allows both parents and medical staff to develop optimal treatment plans in the best interests of the child. AIM OF THE STUDY: The aim of the study was to evaluate factors that may influence the process of decision-making regarding Do-Not-Resuscitate (DNR) status. METHODS: Retrospective single institution study. RESULTS: Totally, 79 patients died between September 01, 2011 and August 31, 2017. Median age of the children was 10.5 years (range, 1 to 24 y). Forty-five were males. There were 37 Muslims, 27 Jews, 9 Druze, and 6 Christians. Twenty-one patients had sarcomas, 20 had CNS tumors, 10 had neuroblastoma, 17 had leukemias/lymphomas, 11 had carcinomas, and other rare tumors as well as nonmalignant diseases. No statistically significant association between all evaluated factors and DNR order status was found. CONCLUSIONS: It is possible that, other than demographic, clinical-associated, or therapy-associated factors play an important role in the process of decision-making regarding DNR. We feel that sincere communication between parents, their child (when appropriate) and medical and psychosocial staff may have a more crucial role when such decisions have to be made.


Assuntos
Diretivas Antecipadas , Ordens quanto à Conduta (Ética Médica) , Adolescente , Diretivas Antecipadas/etnologia , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Estudos Retrospectivos , Adulto Jovem
4.
Pediatr Hematol Oncol ; 24(6): 409-15, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17710658

RESUMO

Despite progress in the treatment of pediatric cancer, approximately 25% of these children will die of the disease. The last period of life is characterized by profound physical and psychological suffering, both of the children and their loved ones. Adequate alleviation of this suffering becomes the priority in the management of these patients. The authors retrospectively evaluated the indications, incidence, and characteristics of palliative sedation (PS) in 19 children with brain tumors (BT) and 18 with sarcomas (S) at the end of life. Twelve of the 18 S patients received PS, as did 13 of the 19 BT patients. Indications for initiation of PS for those with BT were seizures and/or pain, for those with S were pain and/or respiratory insufficiency. It was concluded that PS may be the only efficacious and safe treatment for the alleviation of suffering in these children at the end of life, despite differing indications.


Assuntos
Neoplasias Encefálicas/complicações , Hipnóticos e Sedativos/uso terapêutico , Midazolam/uso terapêutico , Morfina/uso terapêutico , Dor/tratamento farmacológico , Cuidados Paliativos , Insuficiência Respiratória/tratamento farmacológico , Sarcoma/complicações , Convulsões/tratamento farmacológico , Assistência Terminal , Adolescente , Neoplasias Ósseas/complicações , Neoplasias Ósseas/psicologia , Neoplasias Ósseas/terapia , Neoplasias Encefálicas/psicologia , Neoplasias Encefálicas/terapia , Criança , Terapia Combinada , Estado de Consciência/efeitos dos fármacos , Glioma/complicações , Glioma/psicologia , Glioma/terapia , Humanos , Hipnóticos e Sedativos/administração & dosagem , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/secundário , Neoplasias Pulmonares/terapia , Midazolam/administração & dosagem , Morfina/administração & dosagem , Entorpecentes/administração & dosagem , Entorpecentes/uso terapêutico , Tumores Neuroectodérmicos Primitivos/complicações , Tumores Neuroectodérmicos Primitivos/psicologia , Tumores Neuroectodérmicos Primitivos/terapia , Dor/etiologia , Cuidados Paliativos/métodos , Pais/psicologia , Pacientes/psicologia , Insuficiência Respiratória/etiologia , Estudos Retrospectivos , Sarcoma/psicologia , Sarcoma/secundário , Sarcoma/terapia , Convulsões/etiologia , Neoplasias de Tecidos Moles/complicações , Neoplasias de Tecidos Moles/psicologia , Neoplasias de Tecidos Moles/terapia , Estresse Psicológico , Assistência Terminal/métodos , Resultado do Tratamento
5.
J Pediatr Hematol Oncol ; 28(3): 141-6, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16679936

RESUMO

Complementary alternative medicine (CAM) usage and physicians' attitude was evaluated by interviewing all 100 pediatric cancer patients' parents and adolescents seen in the last half of 2003 at Meyer Children's Hospital in Israel. Sixty-one percent of the patients used CAM, an average of 3 different treatments per patient. CAM use was higher: among parents having previous CAM experience (85% vs. 51%, P=0.001) and higher education (79% vs. 50%, P=0.024), and in nonreligious families (71% vs. 50%). Jews and Arabs had similar CAM use rates as with different types of therapies. Socioeconomic status does not affect the rate of CAM use (P=0.9) but does affect the type of treatments used: patients of the higher socioeconomic level mainly used chemi-biological remedies and homeopathy (24% and 28% of interviewees; P=0.002). Middle or lower socioeconomic patients mostly used traditional Arab treatments (32% and 54%, respectively; P=0.012). Only 36% discussed it with their physicians, and most discussions were initiated by parents (79%). Beneficial effect was reported by 69% of CAM users. Most interviewees were interested in getting CAM information and availability in the hospital. Most pediatric cancer patients, regardless of their ethnic origin, use CAM without informing their physicians. Physicians should be aware and know more about it, to be advisors for better integrated care.


Assuntos
Terapias Complementares/estatística & dados numéricos , Neoplasias/tratamento farmacológico , Antineoplásicos/uso terapêutico , Árabes/estatística & dados numéricos , Atitude do Pessoal de Saúde , Criança , Estudos Transversais , Humanos , Israel , Judeus/estatística & dados numéricos , Oriente Médio , Relações Médico-Paciente , Prevalência , Fatores Socioeconômicos , Inquéritos e Questionários
6.
Pediatr Hematol Oncol ; 21(7): 661-8, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15626022

RESUMO

The goal of this study was to evaluate the frequency and timing of "do not resuscitate" (DNR) orders among pediatric oncology patients with progressive solid tumors. A retrospective evaluation of the medical charts of 36 patients who died in our department over the last 4 years was made. There were 21 males and 15 females with a mean age of 10 years (range, 1-22 years). Fourteen patients had brain tumors, 12 had sarcomas, 5 had lymphomas, 4 had neuroblastomas, and 1 suffered from hepatocellular carcinoma. A DNR order was registered in the medical charts of 22 (61%) patients. The DNR was ordered within less than 24 h of death in 5 patients. Median time from DNR order until death was 5 days (range, 0.25-82 days). Place of death was home for 5 (14%) patients, 3 of whom had DNR orders; pediatric oncology ward for 28 (78%), 19 of whom had DNR orders); ICU for 3 (8%), none with a DNR order. Mean time from last day of anticancer treatment until death was 63 days in the group with DNR orders and 56.5 days in the group without DNR orders (p = NS). The study showed that (1) DNR orders were written in only about half the charts of patients with progressive cancer; (2) in several cases, DNR orders were given close to death; and (3) advanced discussion of DNR with parents is needed to reduce parental and medical staff stress accompanying the death of a child and optimizing management of the terminal phase of the disease.


Assuntos
Neoplasias/mortalidade , Ordens quanto à Conduta (Ética Médica) , Atitude Frente a Morte , Criança , Humanos , Prontuários Médicos , Ordens quanto à Conduta (Ética Médica)/ética , Estudos Retrospectivos , Análise de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...